Abstract
Glial cell line-derived neurotrophic factor (GDNF) has previously reduced motor deficits and preserved nigral dopamine neurones in rhesus monkeys with a unilateral MPTP-induced lesion of substantia nigra. We now report on the ability of GDNF to reverse motor deficits induced by parenteral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets resulting in bilateral degeneration of the nigrostriatal pathway. Prior to GDNF administration, all MPTP-treated animals showed akinesia or bradykinesia, rigidity, postural instability and tremor. Intraventricular injection of GDNF (10, 100 or 500 mug) at 9 and 13 weeks post MPTP treatment resulted in a concentration dependent improvement in locomotor activity and motor disability which became significant after administration of 100 and 500 mug of GDNF. The most prominent improvements were in alertness, checking movements, and posture. It is concluded that intraventricular GDNF administration improves bilateral Parkinsonian motor disability following MPTP treatment and this may reflect an action of GDNF on remaining nigral dopaminergic neurones. (C) 2001 Elsevier Science B.V. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 45-50 |
Number of pages | 6 |
Journal | European Journal of Pharmacology |
Volume | 412 |
Issue number | 1 |
Publication status | Published - 19 Jan 2001 |
Keywords
- dopamine
- GDNF (glial cell line-derived neurotrophic factor)
- Parkinson's disease
- MPTP primate
- motor activity
- NIGROSTRIATAL DOPAMINERGIC SYSTEM
- PARKINSONIAN MONKEYS
- GDNF
- NEURONS
- BRAIN
- RECOVERY
- DISEASE
- MODEL
- MICE